Viewing Study NCT03774108



Ignite Creation Date: 2024-05-06 @ 12:28 PM
Last Modification Date: 2024-10-26 @ 12:59 PM
Study NCT ID: NCT03774108
Status: UNKNOWN
Last Update Posted: 2019-12-19
First Post: 2018-12-10

Brief Title: Metformin and Systemic Inflammation in HIV
Sponsor: Hospital Civil de Guadalajara
Organization: Hospital Civil de Guadalajara

Study Overview

Official Title: Metformin Administration Effect Over Systemic Inflammation Serum Markers in HIV Positive Prediabetic Patients
Status: UNKNOWN
Status Verified Date: 2019-12
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: Metfo
Brief Summary: The purposes of this study are to find out if metformin can be combined with anti-HIV drugs to reduce systemic inflammation measured by the determination of cytokines and other series of serum markers To determine if the concomitant administration of metformin with TARA improves the immune function on the CD4 T cell count and its relation with the CD8 T cells during the treatment and after its interruption

To this end in the present study patients with prediabetes who meet the fasting impaired glucose criteria will be identified and treated with metformin or placebo for 8 weeks receiving stable TARA and with a CD4 level 200 cells μL

40 patients from the HIV Unit of the Civil Hospital of Guadalajara Fray Antonio Alcalde will be included in this study and the intervention will last 8 weeks
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None